|
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In our previous study, both trametinib (MEK inhibitor) and CH5126766 (RAF/MEK inhibitor) showed in vitro antitumor effects on neuroblastoma cells with ERK phosphorylation (pERK).
|
30266481 |
2018 |
|
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aimed to overcome crizotinib resistance by combining with the MEK inhibitor trametinib or low-dose metronomic (LDM) topotecan in preclinical neuroblastoma models.
|
28666189 |
2017 |
|
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we sought to define a synergistic therapeutic partner to potentiate MEK inhibition.<b>Experimental Design:</b> We first surveyed 22 genetically annotated human neuroblastoma-derived cell lines (from 20 unique patients) for sensitivity to the MEK inhibitor binimetinib.
|
27729458 |
2017 |
|
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Neuroblastoma New Drug Development Strategy (NDDS) has: 1) established a group with expertise in drug development; 2) prioritised targets and drugs according to tumour biology (target expression, dependency, pre-clinical data; potential combinations; biomarkers), identifying as priority targets ALK, MEK, CDK4/6, MDM2, MYCN (druggable by BET bromodomain, aurora kinase, mTORC1/2) BIRC5 and checkpoint kinase 1; 3) promoted clinical trials with target-prioritised drugs.
|
28604107 |
2017 |
|
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We evaluated the response of neuroblastoma cell lines to MEK-ERK pathway inhibition by trametinib.
|
29184034 |
2017 |
|
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, these findings demonstrated that c-Jun/Fra-1 dimer is critical for neuroblastoma cell growth and that HDACIs act as effective suppressors of the two oncogenes through transcriptionally downregulating MKK7 and Raf1.
|
26734995 |
2016 |
|
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this in-vitro study, we show that MEK inhibitors AZD6244, MEK162 and PD0325901 block cell growth in NRAS mutant neuroblastoma cell lines but not in NRAS wild-type cell lines.
|
26821351 |
2016 |
|
Central neuroblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In neuroblastoma cell lines, we also detected a high frequency of activating mutations in the RAS-MAPK pathway (11/18; 61%), and these lesions predicted sensitivity to MEK inhibition in vitro and in vivo.
|
26121087 |
2015 |
|
Central neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we show that TGFalpha, a known activator of Ras signaling, can drive cell proliferation and at the same time induce the expression of the Notch target Hes-1 in the neuroblastoma cell line SK-N-BE(2)c. The up-regulation of Hes-1 occurred both at the transcriptional and protein levels and by use of EGFR and MEK inhibitors we could show that the Hes-1 response was dependent on activation of the MAP kinase ERK.
|
16120441 |
2005 |
|
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
SH-SY5Y neuroblastoma cells exposed to the complex I inhibitor/parkinsonian neurotoxin methylpyridinium ion (MPP(+)) activate both survival and death-promoting signaling pathways and undergo MEK/ERK-dependent, phosphatidylinositol-3 kinase-dependent, and c-Jun kinase-dependent cell death.
|
12710931 |
2003 |
|
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Rit promotes MEK-independent neurite branching in human neuroblastoma cells.
|
12668729 |
2003 |
|
Central neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We show here, that in the human neuroblastoma cell line SK-N-SH, the membrane impermeable conjugated 17beta-estradiol (E2BSA) activates mitogen activated protein kinase kinase (MAPKK or MEK) and induces the phosphorylation and activation of both ERK-1 and ERK-2 (mitogen activated protein kinase or MAPK).
|
9275096 |
1997 |